Table 2.
Clinical trials of disulfiram (DSF) in cancer therapy.
| NCT number | Conditions | Drugs | Phases | Results |
|---|---|---|---|---|
| NCT00312819 | Non-small Cell Lung Cancer | Chemotherapy, Disulfiram | Phase 2, Phase 3 | Disulfiram was well tolerated and had potential to prolong survival in patients with newly diagnosed non-small cell lung cancer when added to cisplatin and vinorelbine combination regimen. |
| NCT03034135 | Recurrent Glioblastoma | Disulfiram/Copper, Temozolomide | Phase 2 | DSF/Cu in combination with TMZ for TMZ-resistant IDH-wild type GBM seemed to be well tolerated, but had little activity in the unselected group. |
| NCT02101008 | Melanoma | Disulfiram, chelated zinc | Phase 2 | A serious adverse event (1/12) occurred during the trial, that the patient developed psychiatric disorders. |
| NCT01118741 | Prostate Cancer | Disulfiram | Phase 1 | Some patients had transient global PBMC demethylation changes, which limited the efficacy of disulfiram. |
| NCT02678975 | Glioma | Disulfiram, Copper, Alkylating Agents | Phase 2, Phase 3 | Unpublished |
| Glioblastoma | ||||
| NCT03714555 | Metastatic Pancreatic Cancer | Disulfiram, Copper Gluconate, Chemotherapy | Phase 2 | Unpublished |
| NCT00256230 | Stage IV Melanoma | Disulfiram | Phase 1, Phase 2 | Unpublished |
| NCT00742911 | Hepatic metastases from solid tumors | Disulfiram, Copper Gluconate | Phase 1 | Unpublished |
| NCT01907165 | Glioblastoma | Temozolomide, Disulfiram, Copper Gluconate | Early Phase 1 | Unpublished |